Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Iodine-131 Refractory Papillary Thyroid Carcinoma
NCT00559949Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2007
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of selumetinib in Papillary Thyroid Carcinoma (PTC), sponsored by National Cancer Institute. Started Dec 2007; status: completed.
02
Drugs
selumetinib
03
Conditions
Papillary Thyroid Carcinoma (PTC)
Beyond the preview
Go deeper on NCT00559949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00559949.